ABSTRACT
It has been suggested that hyperlipidaemia may contribute to renal disease in diabetes. A number of experimental studies have described the presence of renal lesions associated with abnormal lipid metabolism and suggested the potential influence of dyslipidaemia on the formation of renal injury.1-4 Over the past decade, some clinical studies have attempted to assess the role of lipids in the progression of diabetic nephropathy, in both type 1 and type 2 diabetes.5-7 This chapter reviews the available evidence for a possible role of hyperlipidaemia in the progression of diabetic nephropathy and cardiovascular disease, and addresses the effects of lipid-lowering treatment on the clinical course of diabetic micro-and macrovascular complications.
